Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5239 studies found for:    "Growth Substances"
Show Display Options
Download search resultsDownload the search results for:
"Growth Substances" (5239 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)
Conditions: Respiratory Tract Infections;   Influenza
Interventions: Dietary Supplement: Cholecalciferol (Vitamin D/Vigantol oil);   Dietary Supplement: Miglyol oil
2 Terminated Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
Conditions: Hepatocellular Carcinoma;   Fibrolamellar Hepatocellular Carcinoma
Intervention: Drug: Sutent
3 Recruiting A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Conditions: Metastatic Hepatocellular Carcinoma;   Advanced Liver Cancer
Interventions: Drug: Ascorbic Acid + Sorafenib;   Drug: Sorafenib alone
4 Recruiting Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Condition: Stage IV Pancreatic Cancer
Intervention: Drug: Ascorbic Acid
5 Terminated Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Condition: Stage IV Colorectal Cancer
Intervention: Drug: Vitamin C
6 Terminated Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Conditions: Neuroendocrine Tumors;   Pancreatic Neoplasms;   Advanced Disease;   Sunitinib
Intervention: Drug: Sutent
7 Terminated Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma Non-resectable;   Hepatocellular Carcinoma Recurrent;   Carcinoma, Hepatocellular;   Liver Diseases;   Neoplasms by Histologic Type;   Digestive System Neoplasms;   Carcinoma;   Liver Neoplasms;   Neoplasms;   Neoplasms by Site;   Digestive System Diseases;   Adenocarcinoma;   Neoplasms, Glandular and Epithelial
Interventions: Drug: ABT-869;   Drug: Sorafenib
8 Completed A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
Conditions: HIV Infections;   Peripheral Nervous System Disease
Intervention: Drug: Nerve Growth Factor, Recombinant Human
9 Terminated Growth Hormone and Heart Failure
Condition: Heart Failure, Congestive
Intervention:
10 Completed Patellar Tendon Regeneration With Platelet-rich Plasma
Condition: Knee Instability
Interventions: Procedure: Platelet-rich plasma;   Procedure: Control group
11 Recruiting STUDY WITH LENALIDOMIDE (Revlimid®) MAINTENANCE VS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED MANTLE CELL LYMPHOMA
Condition: MANTLE CELL LYMPHOMA
Intervention: Drug: Lenalidomide
12 Active, not recruiting Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: dovitinib;   Other: laboratory biomarker analysis
13 Recruiting Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus
Conditions: Short Segment Barrett's Esophagus;   Long Segment Barrett's Esophagus
Interventions: Drug: Omeprazole;   Drug: Vitamin D3;   Procedure: upper endoscopy;   Drug: Metformin
14 Active, not recruiting Avastin and Taxotere for Esophagogastric Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Interventions: Drug: Docetaxel;   Drug: Bevacizumab
15 Terminated
Has Results
CoQ10 and Prednisone in Non-Ambulatory DMD
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Prednisone;   Dietary Supplement: Coenzyme Q10
16 Completed Effect of Stellate Ganglion Block on Meniere's Disease
Conditions: Vertigo;   Meniere Disease
Interventions: Procedure: stellate ganglion block;   Drug: 0.25mg, fludiazine;   Drug: 25mg cephadol@ (diphenidol);   Drug: 200mg kentons@ (tocopherol nicotinate).
17 Recruiting Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis
Condition: Chronic Stable Plaque Psoriasis
Interventions: Drug: Clobex Spray;   Drug: Vectical Ointment;   Procedure: Excimer Laser
18 Unknown  Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalidomide;   Drug: idarubicin
19 Completed Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Interventions: Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
20 Active, not recruiting Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab, erlotinib;   Drug: bevacizumab;   Drug: low dose capecitabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years